Coherus BioSciences Inc. (NASDAQ:CHRS) shares were up 1.5% during trading on Tuesday . The stock traded as high as $24.15 and last traded at $23.78, with a volume of 312,673 shares traded. The stock had previously closed at $23.44.

Separately, Zacks Investment Research lowered Coherus BioSciences from a “buy” rating to a “hold” rating in a research report on Tuesday, May 3rd.

The firm’s 50-day moving average is $17.96 and its 200 day moving average is $17.85. The company’s market cap is $933.51 million.

Coherus BioSciences (NASDAQ:CHRS) last issued its earnings results on Monday, May 9th. The company reported ($1.67) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.42) by $0.25. Analysts predict that Coherus BioSciences Inc. will post ($5.90) earnings per share for the current fiscal year.

In related news, insider Peter K. Watler sold 12,000 shares of the stock in a transaction dated Tuesday, May 17th. The stock was sold at an average price of $20.00, for a total value of $240,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Alan C. Herman sold 4,250 shares of the stock in a transaction dated Monday, May 2nd. The shares were sold at an average price of $19.20, for a total value of $81,600.00. Following the completion of the transaction, the insider now directly owns 207,167 shares of the company’s stock, valued at approximately $3,977,606.40. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have modified their holdings of the stock. Jennison Associates LLC increased its position in shares of Coherus BioSciences by 3.1% in the fourth quarter. Jennison Associates LLC now owns 367,021 shares of the company’s stock worth $8,427,000 after buying an additional 11,023 shares in the last quarter. Brown Advisory Inc. increased its position in shares of Coherus BioSciences by 3.0% in the fourth quarter. Brown Advisory Inc. now owns 200,918 shares of the company’s stock worth $4,614,000 after buying an additional 5,937 shares in the last quarter. Finally, CAM Group Holding A S increased its position in shares of Coherus BioSciences by 17.7% in the fourth quarter. CAM Group Holding A S now owns 146,000 shares of the company’s stock worth $3,352,000 after buying an additional 22,000 shares in the last quarter.

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.